Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
March 11, 2025 22:20 ET | Source: Mineralys Therapeutics, Inc. RADNOR, Pa.,…
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving…
Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
March 07, 2025 16:01 ET | Source: Mineralys Therapeutics, Inc. RADNOR, Pa.,…